12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DNA IL-12: Preliminary Phase II data

Preliminary data from 5 evaluable patients in an open-label Phase II trial showed that ImmunoPulse was well tolerated and produced 1 confirmed partial response, defined as a >70% regression of both injected and distal lesion, lasting about 8 months. IL-12 expression levels increased in 3 of 3...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >